A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Adaptive Design Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease.

Trial Profile

A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Adaptive Design Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease.

Suspended
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2015

At a glance

  • Drugs Encenicline (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors EnVivo Pharmaceuticals; FORUM Pharmaceuticals
  • Most Recent Events

    • 14 Sep 2015 According to Forum Pharmaceuticals media release, the US FDA has placed clinical hold on all the studies investigating the effect of encenicline in Alzheimer's disease.
    • 14 Sep 2015 Status changed from completed to suspended, as per Forum Pharmaceuticals media release.
    • 25 Apr 2015 Results presented at the 67th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top